Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | RECQL | P46063 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | APEX1 | P27695 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | BLM | P54132 | 4/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MTOR | P42345 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28471843 | 0.92 | TDP1 (0.50) | TDP1KDM4EMAPK1SHBGADRB2 | |
| SCHEMBL31545523 | 0.83 | PTGS1 (0.61) | TDP1KDM4EMAPK1SHBGSLC6A3 | |
| SCHEMBL529617 | 0.83 | ESR1 (0.48) | TDP1HPGDHSD17B10ALDH1A1BCHE | |
| SCHEMBL2305253 | 0.83 | TDP1 (0.49) | TDP1KDM4EMAPK1SHBGADRB2 | |
| SCHEMBL29459520 | 0.83 | ESR1 (0.48) | TDP1HPGDHSD17B10ALDH1A1BCHE | |
| SCHEMBL27982155 | 0.82 | TDP1 (0.49) | TDP1KDM4EMAPK1SHBGADRB2 | |
| SCHEMBL21851714 | 0.82 | TDP1 (0.56) | TDP1KDM4EMAPK1SHBGADRB2 | |
| SCHEMBL3190368 | 0.81 | BCHE (0.45) | TDP1KDM4EMAPK1SHBGSLC6A3 | |
| SCHEMBL272899 | 0.81 | ALDH1A1 (0.70) | TDP1KDM4EMAPK1SHBGSLC6A3 | |
| SCHEMBL272365 | 0.81 | GAA (0.50) | TDP1KDM4EMAPK1SHBGADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017848-A9 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20250257479-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12320023-B2 | Synthetic method and synthetic system | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| US-20220010436-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | SEKISUI CHEMICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11193212-B2 | Synthetic method and synthetic system | SEKISUI CHEMICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
| EP-3856954-A1 | SYNTHESIS METHOD AND SYNTHESIS SYSTEM | Sekisui Chemical Co., Ltd. (JP) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020067577-A1 | SYNTHESIS METHOD AND SYNTHESIS SYSTEM | SEKISUI CHEMICAL CO., LTD. (JP) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095692-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | SEKISUI CHEMICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| CN-106164029-B | The method for manufacturing the salt and polyetherimide of the aromatic compound of hydroxyl substitution | 沙特基础工业全球技术有限公司 | 2018-06-29 | — | — | CN | disclosed |
| WO-2008097692-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PROTEOTECH INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11193212-B2 | Synthetic method and synthetic system | HCCS, CYP11B2, COX14 | TDP1 3639/4885KDM4E 2045/4885MAPK1 3385/4885 |
| US-20220010436-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | HCCS, CYP11B2, COX14 | TDP1 3639/4885KDM4E 2045/4885MAPK1 3385/4885 |
| US-20200095692-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | HCCS, CYP11B2, COX14 | TDP1 3639/4885KDM4E 2045/4885MAPK1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.